Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

The health sector sees significant developments as Hinge Health raises $437.3 million in its IPO, while the U.S. introduces ...

South Korea's Samsung BioLogics said on Thursday it plans to separate the company between its drug contract manufacturing business, and a business overseeing subsidiaries including biosimilar drug ...

Samsung Biologics announced on May 22 that it will spin off its biosimilar unit, Samsung Bioepis, to create a new holding ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

By Alimat Aliyeva Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it pla ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...